Over the past six months, BD’s shares (currently trading at $224.85) have posted a disappointing 5.9% loss, well below the S&P 500’s 5.1% gain. This
RH’s 23.3% return over the past six months has outpaced the S&P 500 by 18.2%, and its stock price has climbed to $329.50 per share. This run-up might
AbbVie trades at $205.51 per share and has stayed right on track with the overall market, gaining 5.2% over the last six months. At the same time, the
Schneider has been treading water for the past six months, recording a small loss of 3.3% while holding steady at $26.09. The stock also fell short of
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how water
Shareholders of Caleres would probably like to forget the past six months even happened. The stock dropped 59.8% and now trades at $16.98. This was
(Bloomberg) -- Emerging markets were swept up in the global equities storm Friday, with Asian stocks taking the heaviest beating after President Donald
Deborah Elms, head of trade policy for the Hinrich Foundation, said: “I do not know anyone who anticipated another 10% tariff against China so soon."
Even unfilled tariff threats are beginning to alter consumer and business behavior, with markets stumbling on news of yet more sanctions on China.
After two years in the shadows, health stocks are back as a haven for investors navigating economic uncertainty.
